Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Summary: A combination drug called cagrisema helped spur significant weight loss, but missed the bar set by executives, causing shares to fall sharply.
Summary: The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 testing.
Summary: Vertex develops Alyftrek as an enhanced version of their successful cystic fibrosis drug Trikafta.
Summary: The Food and Drug Administration announced that branded tirzepatide, the active ingredient in Eli Lilly’s weight loss drug Zepbound, is no longer in short supply.
Summary: Ikena stockholders will own 34.8% of the combined company, with Inmagene equity holders accounting for 43.5% and investors in a related private placement owning the remaining 21.7%
@ 2024 . All rights reserved
@ 2024 . All rights reserved
